PCSK9 inhibition
PCSK9 inhibitors lower Lp(a) by about 17% in real-world practice, with a bigger effect at higher baseline levels and a smaller effect in women, multi-center study finds (Eur J Prev Cardiol 2025)
Original title: Impact of PCSK9 Inhibitors on Lipoprotein(a) Levels: A Multi-Center Study
This multi-center retrospective study used the University of California Health Data Warehouse to evaluate real-world Lp(a) change among 453 adults prescribed PCSK9 inhibitors with Lp(a) measured before and after starting therapy. Overall, PCSK9 inhibitor use was associated with a median 17.3% (11.3 mg/dL) reduction in Lp(a); among those with baseline Lp(a) above 50 mg/dL, the reduction was 17.7% (19.2 mg/dL). Higher baseline Lp(a) predicted greater reduction (beta -0.31, P < 0.001), while female sex predicted less reduction (beta 9.28, P = 0.02); results held across assay types, PCSK9 inhibitor type, and in patients with serial measurements (n = 274), against a control group of 6,750 individuals whose Lp(a) barely moved (median 0.00 mg/dL) over time. This real-world confirmation of PCSK9 inhibitors' modest, secondary Lp(a)-lowering effect identifies baseline level and sex, not age, race or comorbidities, as the meaningful predictors of response.
Original abstract
Aims: With no currently available targeted therapies for lipoprotein(a) [Lp(a)] lowering, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) may be an option for management of increased cardiovascular risk in individuals with elevated Lp(a). However, Lp(a) lowering with PCSK9i is variable. We aimed to evaluate the real-world change in Lp(a) and predictors of response.
Methods: Using data from the University of California Health Data Warehouse, we conducted a multi-center retrospective study among adults prescribed PCSK9i therapy with available Lp(a) measurement before and after prescription. We evaluated change in Lp(a) compared to baseline and evaluated potential predictors of Lp(a) reduction using multivariable linear regression, including among patients with multiple serial Lp(a) measurements.
Results: Among 453 included individuals, PCSK9i use was associated with a median 17.3 [IQR 35.3, 0.0]% and 11.3 [31.7, 0.0] mg/dL reduction in Lp(a) overall. Among those with Lp(a) >50 mg/dL, a 17.7 [33.6, 0.0]% and 19.2 [42.0, 0.0] mg/dL reduction was observed. Higher baseline Lp(a) level (β -0.31, p<0.001) was a significant predictor of greater Lp(a) reduction, while female sex was associated with less reduction (β 9.28, p=0.02). Results were consistent across Lp(a) assay types and by PCSK9i type and sustained in those with serial Lp(a) measurements (n=274). In contrast, in a control group of 6750 individuals, a median change of 0.00 [-2.00, 3.00] mg/dL in Lp(a) was noted in serial measurements.
Conclusions: PCSK9i are associated with modest Lp(a) lowering of approximately 17% in real-world clinical practice, with a consistent percent reduction by baseline Lp(a) level, PCSK9i type and Lp(a) assay type. Predictors of Lp(a) reduction include baseline Lp(a) level and sex without significant variation by age, race/ethnicity or other evaluated comorbidities.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.